

We are committed to doing our part to advance sustainable practices and minimize our environmental footprint, while working to uphold a reliable supply of medicine. Through our initial companywide sustainability goals and the work we do every day, we actively manage our impact on climate change, energy use, water management and air emissions.

## Advancing our Efforts to Reach our Science-Based Climate Targets

We have set Science Based Targets to reduce absolute scope 1 and 2 GHG emissions by 42% and absolute scope 3 GHG emissions by 25%, in each case by 2030 from a 2020 baseline year. We obtained validation and approval of these targets from The Science Based Targets initiative (SBTi) in 2022, which also classified the target for scope 1 and 2 as aligned with the Paris Agreement's goal of limiting global warming to 1.5°C above pre-industrial levels. Through the end of 2025, we achieved a reduction of our scope 1 and 2 GHG emissions by 17 % and 36% of our scope 3 GHG emissions, from a 2020 base year.

Key pillars in our strategy to reduce GHG emissions and make progress on the SBTi targets are:

- ▶ Increasing renewable energy usage;
- ▶ Implementing energy-efficiency projects and technologies;
- ▶ Using alternative fuels; and
- ▶ Leveraging infrastructure upgrades and utility replacement projects



We reported on our climate program to the CDP, a global nonprofit disclosure system for environmental issues, for the ninth time in 2025. Our results remain above global and industry averages.

Water security: **B**

Climate change: **B**

## Working to Reduce Emissions from Transportation

In 2025, we extended our Mode of Transportation (MOT) Optimization model to more sites. We decreased use of air over the prior year from 52% to 45%, while increasing our use of sea freight over the same time period, to 55% from 48%. Nearly all of our customers now have a default of sea freight on their profiles, and we have made progress on increasing full truckload shipping to optimize the transportation of products.

## Water Stewardship

Water is important to Viatris, not only to our operations and maintaining a resilient supply of medicine, but also, it's important to the communities in which we live and work. We continuously assess and manage water impacts and wastewater streams through risk evaluations, monitoring and regular audits of all Viatris operational sites to ensure compliance with applicable regulations and company water standards.

### *Our Water Goal*

**Our Goal:** Perform water risk assessments for all locations in high or extremely high water-stress areas as identified by the World Resources Institute (WRI) and ascertain appropriate water conservation initiatives by 2025.\*

**Our Progress:** We completed the first phase of our goal in 2024 to perform water risk assessments for all 12 sites identified under high- or extremely high water stress areas. In 2025, we completed three more facilities, which were added by WRI to the list of sites in 2024.

\*Our ability to make progress on our goals depends on several factors, some of which are outside of our control.

## Reducing Waste Across Our Facilities

Reducing waste is important for minimizing environmental impact, conserving natural resources, lowering GHG emissions, and promoting more sustainable practices overall. At Viatris, we have a strong track record of working to reduce waste being sent to landfills, which pose serious environmental challenges including contributing to rising GHG emissions. By advancing zero waste to landfill (ZWL) status across our locations, we are working to reduce our ecological footprint.

In 2025, we achieved ZWL for all our manufacturing and packaging operations in Europe: Chatillon and Meyzieu, France; Komarom, Hungary; Troisdorf, Germany; and in Ireland at Dublin Respiratory, Damastown, both Galway sites and Little Island.

## Viatris' Approach to Sustainable Packaging

Pharmaceutical packaging and labeling are highly regulated with the superior purpose to protect the safety, quality and efficacy of medicines, and appropriate use. In that context, Viatris actively works to explore opportunities to minimize environmental impact. We focus on reducing the volume and types of materials used in packaging while managing and protecting the safety, quality and efficacy of medicines; facilitating patients' administration of medicine; and ensuring access to medicines and maintaining regulatory and quality standards. Cross-functional teams collaborate to minimize packaging waste in both existing products and our product pipeline.



## Our Waste Goal

**Our Goal:** By 2030, increase the number of zero waste-to-landfill (ZWL) locations by 50% from a 2020 baseline – 10 sites increasing to 15.

**Our Progress:** As of 2025, 17 sites across our network have achieved ZWL, exceeding our target.

## Partnering in the Fight Against Antimicrobial Resistance

Viatris is a founding board member of the AMR Industry Alliance (AMRIA), an active member of its Manufacturing Working Group and is committed to partnering across the industry to collectively advance initiatives addressing AMR.

As part of our commitment, we uphold responsible manufacturing in accordance with AMRIA's Antibiotic Manufacturing Standard. All applicable Viatris manufacturing locations with antibiotic production have been internally assessed and adhere to the standard, including meeting the PNEC (RQ<1) as calculated mass balance.

We are continuing our supplier assessment program, to conduct assessments of our top antibiotic suppliers' management and performance. We completed 19 planned audits in 2025.

Five Viatris facilities in Australia, Germany, India and Ireland have received a British Standards Institute (BSI) Kitemark Certification under the AMRIA Manufacturing Standard for meeting standards aimed at minimizing the environmental risk of AMR.

## Stay Connected

Media Relations  
+1.724.514.1968  
Communications@viatris.com

Investor Relations  
+1.724.514.1813  
InvestorRelations@viatris.com

